MicroVention vs. Balt USA: Neurovascular Coil Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | MicroVention, Inc. v. Balt USA, LLC |
| Case Number | 8:19-cv-01335 (C.D. Cal.) |
| Court | U.S. District Court, Central District of California |
| Duration | Jul 2019 – Apr 2024 4 years 9 months |
| Outcome | Dismissed with Prejudice (Each Party Bears Own Costs) |
| Patents at Issue | |
| Accused Products | Balt Optima Coil System, XCEL Detachment Controller |
Case Overview
The Parties
⚖️ Plaintiff
California-based medical device company and subsidiary of Terumo Corporation, specializing in neurovascular intervention products including embolic coils and delivery systems.
🛡️ Defendant
U.S. arm of Balt Group, a French medical device company with a significant presence in the interventional neuroradiology market, competing in the embolic coil segment.
Patents at Issue
This landmark case involved four U.S. patents covering neurovascular embolic coil construction, detachment mechanisms, and delivery system configurations — core functional elements of any competitive neurovascular coil platform.
- • US8182506B2 — neurovascular coil technology
- • US9717500B2 — coil system design
- • US20030154652A1 — earlier-generation embolic device disclosures
- • US9414819B2 — coil delivery and detachment system claims
Developing a neurovascular device?
Check if your product design might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded through a Stipulation of Dismissal (Doc. 371), entered as an order by the court. All claims and counterclaims were dismissed with prejudice, pursuant to Federal Rule of Civil Procedure 41(a).
Critically, each party bears its own attorneys’ fees, costs, and expenses, except for any obligations arising from existing court orders or separate agreements between the parties. No damages figure or injunctive relief was publicly disclosed, suggesting a negotiated resolution.
Verdict Cause Analysis
The most probable explanation for the outcome is a confidential settlement agreement reached between MicroVention and Balt USA. The dismissal with prejudice under Rule 41(a) serves as a final adjudication, preventing re-filing of these specific claims. The agreement for each party to bear its own costs indicates that neither side secured a dominant litigation position compelling a fee award, and avoids the “exceptional case” standard under 35 U.S.C. § 285.
Legal Significance
This case, spanning nearly five years, does not produce a published opinion with precedential claim construction or validity rulings. However, its procedural outcome reflects broader trends in complex medical device patent litigation:
- Multi-patent assertion strategies in medical devices carry significant litigation risk and cost.
- Large defense teams in embolic device cases signal industry recognition that neurovascular patent disputes involve complex technical claims.
- Rule 41(a) stipulated dismissals remain a preferred resolution mechanism when parties reach private resolution after extensive litigation.
Neurovascular Coil FTO Analysis
This case highlights critical IP risks in neurovascular device design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 4 patents involved in this dispute
- See which companies are most active in neurovascular patents
- Understand claim construction patterns for coil technologies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own neurovascular technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Neurovascular Coil Geometry & Detachment
4 Patents at Issue
Covering core coil technology
Design-Around Options
Available for most claim elements
✅ Key Takeaways
Rule 41(a) with-prejudice dismissals with bilateral cost absorption strongly suggest confidential settlement; structure your client’s litigation posture to preserve this exit.
Search related case law →Multi-patent medical device assertions require sustained resource commitment — four patents over five years demands early ROI analysis.
Explore precedents →Frequently Asked Questions
Four U.S. patents: US8182506B2, US9717500B2, US20030154652A1, and US9414819B2 — covering neurovascular embolic coil systems and detachment controller technology.
The parties filed a Stipulation of Dismissal (Doc. 371) under Federal Rule of Civil Procedure 41(a), resulting in dismissal with prejudice. Each party bore its own fees and costs, with a carve-out for obligations under existing court orders or private party agreements.
It reinforces that multi-patent assertions in the embolic coil space are commercially viable pressure mechanisms, but also highlights the substantial defense resources available to market entrants, making early FTO analysis and design differentiation essential for U.S. market entry.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 8:19-cv-01335 (C.D. Cal.)
- USPTO Patent Center
- Cornell Legal Information Institute — 35 U.S.C. § 285
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41(a)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.